A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria

• •Eligibility criteria applicable to all substudies:
• •Men or women 18 to 80 years of age,
• •Ability to provide written informed consent or assent and to be compliant with the schedule of protocol assessments
• •Diagnosed with Crohn's disease (CD) ≥ 3 months
• •Have moderately to severely active CD at Screening
• •Demonstrated inadequate response (ie, primary non-response), loss of response to, or intolerance to ≥ 1 of the following therapies for the treatment of CD:
• •1. Oral corticosteroids (eg, prednisone or its equivalent, budesonide)
• •2. Immunosuppressants (eg, azathioprine \[AZA\], 6 mercaptopurine \[6-MP\], or methotrexate \[MTX\])
• •3. Tumor necrosis factor alpha (TNFα) antagonists (eg, infliximab, adalimumab, certolizumab pegol, or biosimilars)
• •4. Integrin receptor antagonist (eg, vedolizumab)
• •5. Interleukin -12/-23 antagonist (eg, ustekinumab)
• •Females of childbearing potential must be nonpregnant
• •Females of childbearing potential and males must use contraception
• •\- Participants who entered the Extended Induction Period of Substudy 1 and Substudy 2 must have completed the Extended Induction -Week 6 Visit
• •\- Participant must have completed the Week 52 Visit of Substudy 3 or the Week 66 Visit of Substudy A